T2 Diagnosis of T2 asthma in adults - Ian Pavord  Presentation

Participants will learn how to choose the correct skin test method for a specific clinical scenario, how to apply (maximal concentration, criteria for positivity) the skin test and know the factors influencing their diagnostic performance. They will also learn the methods of DPT, indications and contraindications so that they will learn how to decide to administer a DPT and the procedure in detail. They will learn how, when and why to perform BAT. They will improve their knowledge on its diagnostic value depending on the reaction type, the culprit drug and its indications.

The Diagnosis of Drug Allergy – Presentation with CME made available on https://education.eaaci.org/products/diagnosis-ofdrug allergy-presentation-with-cme and organized by EAACI - European Academy of Allergy & Clinical Immunology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists.

Only those e-learning materials that are displayed on the UEMS-EACCME® website have formally been accredited.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

The lecture describes the role of T2 inflammation in the transition from recurrent wheezing to childhood asthma, asthma exacerbations and treatment response. The impact of early life exposures is discussed in depth. Several case studies guide de leaner for understanding personalized decisions in pediatric asthma.

The lecture provides an in depth description of the allergen-specific and general type 2 immune response with tissue and blood eosinophilia, excessive and bad mucus production, tissue remodeling, barrier disfunction, microbial dysbiosis, the role of key cytokines (IL4, IL13, IL5, IL9, TSLP, IL33, IL25). The origins of the T2 response are also discussed, together with the environmental impact. At the end practical examples on how to measure barrier dysfunction are described. 

The lecture describes the two types of chronic rhinosinusitis, with and without nasal polyps, linking its pathogenesis(the complex interplay between the immune-inflammatory response, epithelial barrier defect, mucus and coagulation abnormalities and microbiome) to biomarkers guiding treatment decisions. The inflammatory heterogeneity in CRS impact on clinical phenotypes and disease severity is discussed in depth and is exemplified nicely with clinical cases. 

The lecture describes the two major types of gastro-intestinal inflammatory diseases, IgE and non-IgE, with a special focus on eosinophilic esophagitis, gastritis and colitis. The role of IL 13, IL-5, eotaxin, integrins, epithelial derived cytokines, innate lymphoid cells, genetic defects and environmental insults is discussed in depth in association with personalized treatment approaches. Case reports guide the learner in differentiating the atopic and non-atopic phenotypes of eosinophilic esophagitis. 

The lecture provides an exhaustive description of diagnostic, monitoring, response, predictive and prognostic biomarkers for the T2 immune response, with indications when and how to use in clinical practice followed by an illustrative case report on the value of T2 biomarkers for a non-response to biological intervention in severe asthma. 

Understand the state of omics science specific to asthma and allergic diseases with the current and potential applicability of omics in clinical disease prediction, treatment, and management.

Understand the state of omics science specific to asthma and allergic diseases with the current and potential applicability of omics in clinical disease prediction, treatment, and management.

OVERVIEW

This is a non-promotional, non-CME disease state educational webcast brought to you by EAACI in collaboration with and paid for by GlaxoSmithKline

This webcast is a 4-part series. The topics focus on HES pathophysiology, HES diagnosis and differential diagnosis, HES complications, and HES multidisciplinary assessment.  HES is a heterogeneous group of rare disorders characterised by blood hypereosinophilia, organ dysfunction or damage attributable to tissue hypereosinophilia. The speakers will provide detail on the pathophysiology of HES, with an overview of the causes and variants of HES; discuss how to investigate HES and differentiate it from other diseases; highlight the complications, signs and symptoms that may be associated with HES; and provide clinical insight on the importance of a multidisciplinary approach for personalised assessment and treatment for patients with HES.

EDUCATIONAL OUTCOME/OBJECTIVES

To gain an understanding and clinical insight into:

• the pathogenic role of eosinophils in HES, the mechanisms resulting in eosinophil expansion and the pathogenic contribution of other cells/mediators to HES
• the diagnosis of HES and identifying the cause, how to rule out other disease when diagnosing HES and identify current markers for HES variants
• the broad spectrum of complications associated with HES, and understand the importance of monitoring organs at risk, variability of complications in different disease variants and the nature of the complication in patients with HES
• improving communication between the primary care physician and specialists and understanding why efficient multidisciplinary patient monitoring and treatment is needed.